Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN

Overview of attention for article published in New England Journal of Medicine, December 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 25 news outlets
blogs: 2 blogs
twitter: 143 X users
facebook: 1 Facebook page

reddit: 1 Redditor
bluesky: 27 Bluesky users
podcasts: 2 podcasts

Readers on

mendeley: 58 Mendeley

So far, Altmetric has seen 6 posts from 2 blogs.

#NephMadness 2026: C3G Treatment–The Ultimate Glow-Up Story

AJKD Blog, 08 Apr 2026

Sayna Norouzi @SaynaNorouzi – @saynanorouzi.bsky.social Sayna Norouzi is an associate professor of Medicine and clinical…

2026 #NephJCKidneys vote begins

Blog - NephJC, 06 Mar 2026

After an extended nomination period, it is time to vote for your favorites. Like in the previous years, you will need to be a…

#NephMadness 2026: C3G Region

AJKD Blog, 01 Mar 2026

Submit your picks! | @NephMadness | @nephmadness.bsky.social | NephMadness…

TenPosts: pegcetacoplan in C3GN

Blog - NephJC, 16 Jan 2026

Check out VALIANT recap: a 26-week analysis of the phase 3 trial of pegcetacoplan in C3GN! Thread by NephJC intern Bogdan…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity, including 2 additional blog posts.